SGMO Quote, Financials, Valuation and Earnings

bluebird bio has a net margin of -309.84% compared to Sangamo Therapeutics's net margin of -573.01%. Sangamo Therapeutics's return on equity of -217.48% beat bluebird bio's return on equity of -245.94%.

Sangamo Therapeutics has a consensus price target of $5.00, signalling upside risk potential of 661.62%. On the other hand bluebird bio has an analysts' consensus of $6.50 which suggests that it could grow by 31.31%. Given that Sangamo Therapeutics has higher upside potential than bluebird bio, analysts believe Sangamo Therapeutics is more attractive than bluebird bio.

Sangamo Therapeutics has a beta of 1.570, which suggesting that the stock is 57.032% more volatile than S&P 500. In comparison bluebird bio has a beta of 0.431, suggesting its less volatile than the S&P 500 by 56.869%.

Sangamo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. bluebird bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sangamo Therapeutics pays -- of its earnings as a dividend. bluebird bio pays out -- of its earnings as a dividend.

Sangamo Therapeutics quarterly revenues are $7.6M, which are smaller than bluebird bio quarterly revenues of $10.6M. Sangamo Therapeutics's net income of -$23.4M is higher than bluebird bio's net income of -$60.8M. Notably, Sangamo Therapeutics's price-to-earnings ratio is -- while bluebird bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sangamo Therapeutics is 2.30x versus 0.57x for bluebird bio. Usually stocks with elevated PS ratios are considered overvalued.

Inovio Pharmaceuticals has a net margin of -309.84% compared to Sangamo Therapeutics's net margin of -16566.39%. Sangamo Therapeutics's return on equity of -217.48% beat Inovio Pharmaceuticals's return on equity of -119.02%.

Sangamo Therapeutics has a consensus price target of $5.00, signalling upside risk potential of 661.62%. On the other hand Inovio Pharmaceuticals has an analysts' consensus of $7.83 which suggests that it could grow by 402.14%. Given that Sangamo Therapeutics has higher upside potential than Inovio Pharmaceuticals, analysts believe Sangamo Therapeutics is more attractive than Inovio Pharmaceuticals.

Sangamo Therapeutics has a beta of 1.570, which suggesting that the stock is 57.032% more volatile than S&P 500. In comparison Inovio Pharmaceuticals has a beta of 1.837, suggesting its more volatile than the S&P 500 by 83.748%.

Sangamo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inovio Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sangamo Therapeutics pays -- of its earnings as a dividend. Inovio Pharmaceuticals pays out -- of its earnings as a dividend.

Sangamo Therapeutics quarterly revenues are $7.6M, which are larger than Inovio Pharmaceuticals quarterly revenues of $117K. Sangamo Therapeutics's net income of -$23.4M is lower than Inovio Pharmaceuticals's net income of -$19.4M. Notably, Sangamo Therapeutics's price-to-earnings ratio is -- while Inovio Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sangamo Therapeutics is 2.30x versus -- for Inovio Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -309.84% compared to Sangamo Therapeutics's net margin of 35.65%. Sangamo Therapeutics's return on equity of -217.48% beat Protalix BioTherapeutics's return on equity of 8.75%.

Sangamo Therapeutics has a consensus price target of $5.00, signalling upside risk potential of 661.62%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 506.7%. Given that Sangamo Therapeutics has higher upside potential than Protalix BioTherapeutics, analysts believe Sangamo Therapeutics is more attractive than Protalix BioTherapeutics.

Sangamo Therapeutics has a beta of 1.570, which suggesting that the stock is 57.032% more volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.351%.

Sangamo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sangamo Therapeutics pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Sangamo Therapeutics quarterly revenues are $7.6M, which are smaller than Protalix BioTherapeutics quarterly revenues of $18.2M. Sangamo Therapeutics's net income of -$23.4M is lower than Protalix BioTherapeutics's net income of $6.5M. Notably, Sangamo Therapeutics's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 79.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sangamo Therapeutics is 2.30x versus 3.71x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Quanterix has a net margin of -309.84% compared to Sangamo Therapeutics's net margin of -34.09%. Sangamo Therapeutics's return on equity of -217.48% beat Quanterix's return on equity of -11.35%.

Sangamo Therapeutics has a consensus price target of $5.00, signalling upside risk potential of 661.62%. On the other hand Quanterix has an analysts' consensus of $14.50 which suggests that it could grow by 144.11%. Given that Sangamo Therapeutics has higher upside potential than Quanterix, analysts believe Sangamo Therapeutics is more attractive than Quanterix.

Sangamo Therapeutics has a beta of 1.570, which suggesting that the stock is 57.032% more volatile than S&P 500. In comparison Quanterix has a beta of 1.351, suggesting its more volatile than the S&P 500 by 35.098%.

Sangamo Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quanterix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sangamo Therapeutics pays -- of its earnings as a dividend. Quanterix pays out -- of its earnings as a dividend.

Sangamo Therapeutics quarterly revenues are $7.6M, which are smaller than Quanterix quarterly revenues of $34.1M. Sangamo Therapeutics's net income of -$23.4M is lower than Quanterix's net income of -$11.6M. Notably, Sangamo Therapeutics's price-to-earnings ratio is -- while Quanterix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sangamo Therapeutics is 2.30x versus 1.68x for Quanterix. Usually stocks with elevated PS ratios are considered overvalued.